BRAF and central nervous system cancer: Certain glioma-associated biomarkers can be assessed by immunohistochemistry, including IDH1 R132H [12], H3 K27M and H3 G34R/V [13–15], loss of nuclear ATRX expression [16], and BRAF V600E mutation [17].